Project Name：Aprepitant 

Registration Classification：3.1

Formulations and specifications ：Capsules: 80mg, 125mg 

Indications：Prevention of acute and delayed chemotherapy-induced nausea and vomiting.

Original Research Company：Merck 

Progress ：Pharmaceutical Research in progress